L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

NCT05775705 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

PD-1 Antibody
Hemophagocytic Lymphohistiocytosis
Epstein-Barr Virus
Lymphoma

Interventions

DRUG: L-DEP and PD-1 antibody

Sponsor

Beijing Friendship Hospital